[{"id":"b7a36882-65b3-44a2-abdd-b0fe4500256d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03809624","created_at":"2021-07-22T21:52:31.520Z","updated_at":"2024-07-02T16:35:18.390Z","phase":"Phase 2","brief_title":"Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer","source_id_and_acronym":"NCT03809624","lead_sponsor":"Inhibrx, Inc.","biomarkers":" TMB","pipe":" | ","alterations":" TMB-H","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • enristomig (INBRX-105)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-21"},{"id":"d316c09c-f20b-4a7c-abde-115107c4593c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04841538","created_at":"2021-04-12T15:52:37.016Z","updated_at":"2024-07-02T16:36:11.223Z","phase":"Phase 1b/2","brief_title":"A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors","source_id_and_acronym":"NCT04841538","lead_sponsor":"Elpiscience Biopharma, Ltd.","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enristomig (INBRX-105)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2022-04-29"}]